orbimed english  portfolio immunotherapy gene therapy gene editing the future of health sciences is closer than you think many technologies with the potential to cure disease are advancing rapidly how long can healthy humans live  years  years our portfolio companies are working hard to find out industry sector all biopharmaceutical diagnosticstools healthcare services medical device healthcare it region all asia middle east north america europe sort by alphabetical newest oldest acutus developing a novel electroanatomical mapping catheter more adaptimmune focused on the use of t cell therapy to treat cancer more adicet bio adicet bio inc is developing a novel universal immunecell more adimab fully integrated yeastbased antibody discovery maturation and more aeglea biotherapeutics developing novel treatments using engineered human amino more aerpio developing treatments for disorders of the vasculature with more affimed discovering and developing next generation antibody therapies more aige hospital a leading eye hospital chain in the central region of china more aims multispecialty tertiary care hospital in north india more ait applied immune technologies ait is a drug development more ak medical developing a novel electroanatomical mapping catheter for more alector developing antibody therapeutics to treat more alpine immune sciences alpine immune sciences is focused on developing novel more amoy diagnostics the leader in cancer molecular diagnostics in china more armo biosciences discovering and developing novel immunooncology drugs more arsanis biosciences developing antibody therapeutics for infectious diseases more arvinas arvinas is a pharmaceutical company focused on developing more ascendis pharma ascendis pharma develops differentifaated prodrug versions more atox bio atox bio is a late stage biotechnology company that develops more audentes therapeutics developing gene therapy products for rare diseases more augmedix augmedix commercializes a service that frees doctors from more avedro inc avedro is a privately held medical device and more avitide developing custom affinity purification solutions for more balance therapeutics balance therapeutics is an rd company focused on more bharat serums and vaccines developing and manufacturing a wide range of products such more biolinerx building a portfolio of products for various indications more bonovo orthopedics providing the latest orthopedic products to the more cbt pharmaceuticals a spinoff from crown biosciences dedicated to oncology more cerapedics developing and commercializing products for the orthopedic more chemclin a leader to provide affordable diagnostics products more chemomab chemomab is developing therapeutic antibodies as more cleave biosciences discovering and developing therapeutics targeting more clementia developing treatments for diseases of heterotopic more compass therapeutics compass therapeutics is seeking to cure various cancer more corvus pharmaceuticals developing novel immunotherapies for the treatment of cancer more credit pharma credit pharma is a central nervous system focused leading more crown bioscience a preclinical cro with leadership in translational oncology more dih a leading provider of robotics and intelligent systems more dimension therapeutics developing aav therapeutics for rare diseases more domain surgical develops and commercializes a thermal surgical energy more echosens french hightechnology company specializing in more eddingpharm commercializing a broad range of pharmaceutical products in more emendo biotherapeutics emendo develops biotherapeutics based on its novel gene editing more eurolife healthcare one of india’s leading manufacturers of intravenous iv fluids more futurx pharma incubator established with jj and takeda more gc aesthetics develops and manufactures breast and aesthetic implants for more gcrise pharmaceutical a leading chinese pharmaceutical company focused on women more genewiz a leading global genomics service company more glaukos transforming glaucoma therapy more good start genetics developing improved methods of prepregnancy testing more graybug vision graybug vision is developing products to reduce the frequency of more guardant health guardant health is a private diagnostics company focusing on more hls therapeutics hls therapeutics is a specialty pharmaceutical more igenica discovering and developing breakthrough more inspire medical systems developed implanted neurostimulation device for more intellia therapeutics intellia is a leading gene editing company focused on more intercept developing therapeutics for liver  metabolic diseases more invitae offering  genetic diagnostics for hereditary disorders more kala pharmaceuticals kala pharmaceuticals is a clinical stage pharmaceutical more keystone heart developing procedural tools and accessories for use during more laxmi dental leading dental laboratory in india manufacturing dental more logicbio logicbio develops gene therapy vectors for previously more loxo oncology developing targeted cancer therapies for more marinus pharmaceuticals marinus pharmaceuticals is a clinical stage more mdclone mdclone was founded to address one of the most critical more medigus developing innovative endoscopic procedures and devices more mid labs an innovative ophthalmic medical device company with more nabriva developing pleuromutilins a new class of antibiotics more natera provides preconception and prenatal genetic testing more nerre therapeutics nerre therapeutics is developing a portfolio of neurokinin more netmedscom netmedscom is a leading online pharmacy marketplace in india more nextcure nextcure is a biopharmaceutical company focused on more novellusdx a personalized medicine diagnostics company assessing the more nucleix nucleix develops manufactures and markets more nutrinia nutrinia treats rare diseases of the gi tract by developing more obseva sa obseva is a swissbased pharmaceutical company developing small more omniguide surgical develops and markets an advanced surgical energy delivery more oric pharmaceuticals oric pharmaceuticals is focused on discovering and more ornim medical developing devices monitoring hemoglobin blood more otic pharma oticpharma is seeking to develop ear nose and throat products more otonomy developing novel drug therapies for disorders of the inner more oxonc development conducting clinical studies of xalkori in ros advanced more pharmabcine developing fully human therapeutic antibodies for the more pharming group nv netherlandsbased public biotechnology company more pieris ag discovering and developing anticalins® a novel class more pionyr immunotherapeutics pionyr is developing cancer immunotherapies that target the more pmv pharma developing p modulators for the treatment of cancer more practice fusion a leading provider of electronic healthcare record services more principia biopharma developing novel therapeutics using reversible more promentis pharmaceuticals promentis is developing compounds for the treatment of cns more proteus digital health proteus is a private digital medicine platform company more rapid pathogen screening marketer of rapid pointofcare diagnostic tests more rdd pharma developing drugdevice combinations for the treatment more recro pharma clinical stage specialty pharmaceutical company more redhill biopharma developing late clinicalstage formulations and combinations more response biomedical corp manufactures and markets rapid onsite diagnostic tests more reviral reviral is an emerging ukbased biopharma aiming to more rhythm pharmaceuticals rhythm is a biopharmaceutical company developing more roka bioscience commercializing novel nucleic acid testing methods more rpharm rpharm us is a specialty pharmaceutical company focused on more scpharmaceuticals scpharmaceuticals is developing a portfolio of pharmaceutical more selecta biosciences developing firstinclass integrated synthetic more senico healthcare leading provider of kidney and specialty care services in the more sibone commercializing the ifuse implant system for minimally more sientra inc developing products for the plastic surgery and more sierra oncology sierra oncology is a clinical stage drug development company more sikka software enhancing practice economics and improving quality of care more singulex developing and commercializing the next generation of more smartzyme smartzyme innovation is a life science company using a more sonendo developing innovative devices for root canal treatment more steadymed steadymed is a specialty pharmaceutical company focused on the more strides shasun service provider to the global pharmaceutical industry more suraksha diagnostic leading diagnostic chain in east india more surya a prominent neonatal and pediatric care hospital chain more symbiomix therapeutics a new focus on womens health more syndax pharmaceuticals syndax is a latestage biopharmaceutical company more synlogic synlogic engineers synthetic biotics a new class of medicines more tela bio developing novel biologic mesh implant products more therachon therachon is a biotech company specialized in research and more tigertext provides secure messaging in healthcare applications more tp therapeutics tp therapeutics is a clinicalstage biopharmaceutical company more treato the voice of the patient  big data analytics of patient more tricida preclinical stage biopharmaceutical company focused on more turnstone biologics turnstone is developing a firstinclass engineered oncolytic more tyto tytocare provides the missing link in telehealth  a more unilife develops and supplies injectable drug delivery systems more upper biotech a leading poct diagnostics company in china more verona pharma verona pharma is a ukbased clinical stage biopharmaceutical more viewray developing next generation radiotherapy technologies more waterstone pharmaceuticals chinabased specialty pharmaceutical company more whale imaging developing and commercializing medical imaging solutions more xenon pharmaceuticals xenon is a clinicalstage biopharmaceutical company discovering more xtant medical xtant medical is a comprehensive supplier of orthopedic more zai labratory a leading biotech company based in china more load more our team has helped nurture and commercialize some of todays most successful healthcare companies meet our team orbimed english  contact us orbimeds team includes over  experienced professionals with expertise in the life sciences industry medicine finance and law investors if you are an investor interested in learning more about our funds please contact carter neild or bill price at    or send us an email companies if you would like to meet with our team please send us a description of your firm and the type of financing you are seeking by email for general inquiries please contact us at      new york  lexington avenueat rd street th floornew york ny       san francisco  mission bay blvd southsuite san francisco ca       mumbai suite f  grand hyatt plazasantacruz eastmumbai  india       herzliya  medinat hayehudim stbuilding e th floorherzliya  israel      shanghai unit  raffles cityshanghai office tower xizang middle roadshanghai  pr china    our team has helped nurture and commercialize some of todays most successful healthcare companies meet our team orbimed english  about us from biopharmaceuticals to medical devices diagnostics and healthcare services orbimed is scouting the globe for innovations that will help ensure humanity lives healthier longer and more productive lives we have been investing globally for over  years across the healthcare industry from earlystage private companies to large multinational corporations our team of over  distinguished scientific medical investment and other professionals manage approximately  billion across public and private company investments worldwide   life sciences focus the global healthcare industry sits at the intersection of several powerful longterm growth trends led by global demographics and the ineluctable advance of scientific innovation in treating disease these trends have caused a steady increase in the level of healthcare spending in the industrialized world led by the us which now spends over  of its gdp on healthcare the healthcare industrys powerful growth profile coupled with its magnitude and complexity create myriad investment opportunities our strategies orbimed invests across the global healthcare industry from seedstage venture capital to large publiclytraded companies investments are made in one of three strategies public equity private equity and royalty opportunities public equity orbimed manages a series of public equity funds including longshort eventdriven funds and closedend investment trusts we invest across all types of publiclytraded companies from biopharmaceuticals to medical devices and healthcare services worldwide private equity orbimeds private equity strategy is broad and flexible investing from startups through growth equity orbimed is typically a lead investor seeking to help build our portfolio companies our geographic focus includes north america asia europe and israel royalty opportunities orbimed provides commercialstage healthcare companies with nondilutive structured debt capital additionally orbimed can monetize royalty streams providing valuable financing solutions to owners of intellectual property firm history to thrive organisms need to adapt and grow so do investment firms through  years of volatile changing investment environments weve embraced new opportunities and expanded our global footprint    orbimeds investment business was founded in new york city    launched our first longshort fund and made our first venture capital investment    launched our first dedicated venture capital fund    opened offices in san francisco and shanghai china    opened office in mumbai india    opened office in herzliya israel    launched our first dedicated royalty  credit fund    hired our th employee our team has helped nurture and commercialize some of todays most successful healthcare companies meet our team bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version insider trading  orbimed capital gp v llc  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  orbimed capital gp v llc select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm loxo oncology inc loxo orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector    indirect view purchase  pm corvus pharmaceuticals inc crvs orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner    indirect view purchase  pm corvus pharmaceuticals inc crvs orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner    indirect view purchase  pm corvus pharmaceuticals inc crvs orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner    indirect view purchase  pm corvus pharmaceuticals inc crvs orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner    indirect view purchase  pm adaptimmune therapeutics plc adap orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector    indirect view purchase  pm corvus pharmaceuticals inc crvs orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner    indirect view purchase  pm corvus pharmaceuticals inc crvs orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector    indirect view purchase  pm intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector    indirect view purchase  pm dimension therapeutics inc dmtx orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner    indirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view conversion  pm nana dimension therapeutics inc dmtx orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner   indirect view conversion  pm nana dimension therapeutics inc dmtx orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner   indirect view conversion  pm nana dimension therapeutics inc dmtx orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner   indirect view conversion  pm nana dimension therapeutics inc dmtx orbimed advisors llcorbimed capital gp v llcisaly samuel ddirector owner   indirect view   secformcom all rights reserved archives        thu  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  orbimed capital gp v llc  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors orbimed capital gp v llc check out list of companies and businesses related to orbimed capital gp v llc find out orbimed capital gp v llc address and contact details view other people related to orbimed capital gp v llc  coworkers colleagues companions etc address  lexington avenue th floor new york  ny companies related to orbimed capital gp v llc cikcompany namepositioncompany addressaerpio pharmaceuticals inc carver road cincinnati loxo oncology inc tresser boulevard th floor stamford dimension therapeutics inc memorial drive th floor cambridge adaptimmune therapeutics plc park drive milton park abingdon oxfordshire ox rycorvus pharmaceuticals inc mitten road suite  burlingame aeglea biotherapeutics inc s mopac expressway ste  barton oaks plaza one austin nabriva therapeutics plc fitzwilliam square dublin intellia therapeutics inc erie street suite  cambridge  orbimed capital gp v llc on the web persons related to orbimed capital gp v llc  aerpio pharmaceuticals incnamepositioncitydalal anupamcincinnaticastelein caleycincinnaticaley casteleindirector grand prairiekhuong chaucincinnatianupam dalalcambridgepravin dugelcincinnatijoseph h gardnersee remarks cincinnatisamuel d isalymurphy jamescincinnatigardner josephcincinnatipeters kevincincinnatichau quang khuongdirector san diegomatthew p kinleydes moinessatter muneercincinnatijames b murphywalthamag novartisch baselnovartis bioventures ltd owner hamiltonorbimed advisors llcdirector steve pakolacincinnatijohn pappajohndes moinesweiss paulcincinnatikevin g peterschief scientific officer cincinnatidugel pravincincinnatisteven prelacknewtonmuneer a satterdirector new yorkpakola stephencincinnatiprelack stevencincinnatiargyris vassilioulong island citypaul m weissdirector bloomfieldpersons related to orbimed capital gp v llc  loxo oncology incnamepositioncityaccess industries management llcnew yorkai loxo holdings llc owner new yorkai value holdings llcnew yorkaisling capital iii lp owner new yorkaisling capital iii lp owner new yorkaisling capital partners iii llcnew yorkaisling capital partners iii llcnew yorkaisling capital partners iii lpnew yorkaisling capital partners iii lpnew yorkarray biopharma inc owner bouldernaider avistamfordm james barrettdirector baltimorem james barrettdirector timoniumpeter j barris owner timoniumforest baskett owner timoniumjoshua h bilenkerpresident  ceo warrenlen blavatniknew yorkdavid p bonitadirector san diegodavid p bonitadirector stamfordjennifer bursteinvice president of finance stamfordbonita davidstamforddeerfield international master fund lpnew yorkmanagement co deerfieldnew yorkdeerfield mgmt lpnew yorkdeerfield mgmt lpnew yorkdeerfield partners lpnew yorkdeerfield special situations fund lpnew yorkdeerfield special situations fund lpnew yorkdeerfield special situations international master fund lpnew yorkgoldstein dovnew yotkgoldstein dovstamfordryan d drant owner timoniumsteve elmsdirector chestersteve elmsdirector new yorkkeith t flahertydirector boulderkeith t flahertydirector stamfordanthony a jr florence owner chevy chasejames e flynn owner new yorkjames e flynnnew yorkalan fuhrmandirector bothellalan fuhrmandirector stamforddov a md goldsteincfo and treasurer king of prussiadov a md goldsteincfo and treasurer stamfordsteve harrdirector seattlesamuel d isalysamuel d isalynew yorkbarrett jamesstamfordbilenker joshuanew yorkbilenker joshuastamfordflaherty keithstamfordpatrick j kerins owner timoniumkrishna kittu kolluri owner timoniumlori anne kunkeldirector sunnyvalelori anne kunkelstamfordjennifer a lowchief medical officer stamfordtimothy m maylebendirector ann arbordavid m mott owner timoniummikel paul moyerstamfordavi z naiderdirector stamfordnea  gp ltdtimoniumnea partners  lptimoniumnew enterprise associates  lp owner timoniumorbimed advisors llcdirector orbimed advisors llc owner new yorkdennis j purcellnew yorkdennis j purcellnew yorkscott d sandell owner timoniumandrew n schiffnew yorkdr drew schiffnew yorkpeter w sonsini owner menlo parkelms stevennew yorkelms stevenstamfordnaarden jacob vanchief business officer stamfordravi viswanathan owner timoniumharry r weller owner timoniumpersons related to orbimed capital gp v llc  dimension therapeutics incnamepositioncityfox allancambridgejenkins annalisacambridgeauspitz benjamincambridgek reed clarksvp of pharmaceutical develop cambridgealan colowickdirector redwood cityeric crombezchief medical officer cambridgehayden donaldcambridgehayden donaldcambridgehayden jr donaldcambridgemichael dybbsdirector new yorkfmr corp owner bostonjean m franchichief financial officer cambridgegeorges gemayeldirector cambridgerishi guptadirector mountain viewjohn hohnekerdirector cambridgesamuel d isalyhachigian jaybostonannalisa jenkinspresident and ceo fremontgeorge v migauskydirector gaithersburgarlene morrisdirector san diegoorbimed advisors llcdirector gupta rishicambridgemary thistlechief operating officer cambridgebeck thomascambridgesamuel c wadsworthchief scientific officer cambridgepersons related to orbimed capital gp v llc  adaptimmune therapeutics plcnamepositioncitybehbahani alitimoniumlawrence m allevadirector walthamrafael amadochief medical officer malvernm james barrett owner baltimorepeter j barris owner baltimoreforest baskett owner baltimoreali behbahanidirector timoniumwilliam c bertrand jrgaithersburggwendolyn knowlton binderschollchief technology officer philadelphiamott davidtimoniumjonathan knowles drabingdon oxfordshirebarbara gayle duncandirector somersetsigal elliottprincetonanthony a jr florence owner chevy chaselaing ianabingdon oxfordshiresamuel d isalynoble jamesabingdon oxfordshirepatrick j kerins owner baltimoregiles francis bertram kerrdirector oxfordshirejonathan kenneth charles knowlesdirector basellandkrishna kittu kolluribaltimoreian michael laingdirector oxforddavid m mottdirector gaithersburgnea  gp ltdtimoniumnea partners  lptimoniumnew enterprise associates  lp owner timoniumjames noblechief executive officer branfordorbimed advisors llcdirector thompson peternew yorkadrian rawcliffechief financial officer brentford middlesex englandscott d sandell owner baltimorecharles elliott sigaldirector princetonpeter w sonsini owner menlo parkhelena katrina taytonmartinchief operating officer hungerfordpeter a thompsondirector bellevueravi viswanathan owner timoniumharry r wellerbaltimoretal zvi zaksdirector newtonpersons related to orbimed capital gp v llc  corvus pharmaceuticals incnamepositioncityadams street partners llc owner chicagoian t clarkdirector so san franciscojason v colomasvp chief business officer burlingameterry gould elishachicagoterry p goulddirector redwood citysamuel d isalywilliam benton jonesvp pharmaceutical development burlingamesteve e krognesdirector burlingameleiv leachief financial officer sunnyvalelea leivportola valleylea leivburlingamerichard a md millerpresident and ceo sunnyvalepeter moldtburlingamescott w morrisonsouth san franciscoas novo owner bagsvaerdorbimed advisors llcdirector moldt peterkellenupthompson peternew yorkmiller richardportola valleymiller richardburlingamegould terrychicagopeter a thompsondirector bellevueerik j vernervp chemistry research burlingamepersons related to orbimed capital gp v llc  aeglea biotherapeutics incnamepositioncityshanafelt armenaustinsuzanne louise bruhndirector novatoyork charlesaustinrussell j coxdirector palo altolowe davidaustingeorgiou georgeaustingeorge georgioudirector austinhenry hebelvp product development austinskinner henryaustinsamuel d isalylilly eli  co owner indianapolislilly ventures fund i llcsan diegodavid george loweceo and president palo altosandesh mahatmedirector summitag novartisch baselnovartis bioventures ltd owner hamiltonorbimed advisors llc owner anthony quinninterim chief medical officer lexingtonsandra rojascarochief medical officer austinscott w rowlinsonvp research austinaaron schuchartchief business officer austinarmen shanafeltdirector indianapoliss edward torressan diegojoseph e tylervp manufacturing cambridgejames wooldridgeaustincharles n york iichief financial officer and vp austinpersons related to orbimed capital gp v llc  nabriva therapeutics plcnamepositioncityaxel boltesouth plainfieldcolin md broomchief executive officer extondaniel d burgesssan diegomark corriganmarlboroughrobert crottyseattlesteven p gelonechief development officer king of prussiahbm bioventures cayman ltd owner grand caymansamuel d isalychau quang khuongsan diegoorbimed advisors llccharles a rowland jrchadds fordelyse g seltzerchief medical officer king of prussiagary senderchief financial officer new yorkgeorge harrison talbotdirector morristownvivo capital viii llcpalo altostephen w websterextonjohn peter wolf iiiextonpersons related to orbimed capital gp v llc  intellia therapeutics incnamepositioncityatlas venture associates ix lp owner cambridgeatlas venture associates ix llccambridgeatlas venture fund ix lp owner cambridgebaker bros advisors gp llcnew yorkbaker bros advisors llc new yorkfelix bakerjulian bakerthomas m barnessvp rd extellia cambridgegraeme bellevp chief financial officer palo altonessan berminghampresident  ceo cambridgecaribou biosciences incberkeleycaribou therapeutics holdco llc owner berkeleygordon carlcambridgecaroline dorsadirector whitehouse stationforesite capital fund iii lpsan franciscoforesite capital management iii llcsan franciscojean francois formeladirector fullerton management pte ltdsingaporecarl l gordondirector new yorkrachel e haurwitzdirector cambridgenicole heifnersvp accounting cambridgesamuel d isalyformela jeanfrancoiscambridgeleonard johncambridgerivera josecambridgeperry a karsendirector rockvillejohn m leonardevp rd north chicagodavid v morrisseysvp platform  delivery tech cambridgebermingham nessancambridgeag novartisch baselnovartis institutes for biomedical research inc owner cambridgeorbimed advisors llcdirector orbimed global healthcare gp llcnew yorkhaurwitz rachelcambridgejose e riveraevp general counsel  ops cambridgemoncef slaouidirector cambridgesapna srivastavacedar knollsjames b tananbaumsan franciscotemasek holdings ltd owner singaporetemasek life sciences private ltdsingaporetls beta pte ltdsingaporefrank verwieldirector brisbane orbimed advisors llc sc da filing concerning adap on  whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active schedule da filed by orbimed advisors llc total shares  subject company adaptimmune therapeutics plc  view complete ownership history backtest filed as of date  event date  overall  ownership  reporting persons name solevoting power sharedvoting power soledispositive power shareddispositive power aggregateamount owned percentof class orbimed advisors llc       orbimed capital gp v llc       samuel d isaly       view original filing on edgars raw filing contents txt   hdrsgml    accession number  conformed submission type sc da public document count  filed as of date  date as of change  group members orbimed capital gp v llc group members samuel d isaly subject company company data company conformed name adaptimmune therapeutics plc central index key  standard industrial classification biological products no diagnostic substances  irs number  state of incorporation x fiscal year end  filing values form type sc da sec act  act sec file number  film number  business address street   park drive street  milton park city abingdon oxfordshire state x zip ox ry business phone    mail address street   park drive street  milton park city abingdon oxfordshire state x zip ox ry former company former conformed name adaptimmune ltd date of name change  filed by company data company conformed name orbimed advisors llc central index key  irs number  state of incorporation de filing values form type sc da business address street   lexington avenue street  th floor city new york state ny zip  business phone   mail address street   lexington avenue street  th floor city new york state ny zip  sc da  ssscdahtm amendment no      united states securities and exchange commission washington dc    schedule d under the securities exchange act of  amendment no      adaptimmune therapeutics plc name of issuer     ordinary shares title of class of securities     a cusip number orbimed advisors llc orbimed capital gp v llc samuel d isaly    lexington avenue th floor new york ny  telephone    name address and telephone number of person authorized to receive notices and communications     november   date of event which requires filing of this statement   if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of § de df or dg check the following box o   note  schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits  see § db for other parties to whom copies are to be sent   the remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page   the information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section  of the securities exchange act of  “act” or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes                schedule d   cusip no  a   page  of  pages            name of reporting persons     orbimed advisors llc  check the appropriate box if a member of a group see instructions a o b o        sec use only      source of funds see instructions   af  check box if disclosure of legal proceedings is required pursuant to items d or e     o  citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with  sole voting power     shared voting power     sole dispositive power     shared dispositive power     aggregate amount beneficially owned by each reporting person     check box if the aggregate amount in row  excludes certain shares see instructions     o  percent of class represented by amount in row      type of reporting person see instructions   ia  this percentage is calculated based upon  of the issuer’s ordinary shares outstanding including any such ordinary shares represented by adss defined below as set forth in the issuer’s form f filed with the sec defined below on october            schedule d   cusip no  a   page  of  pages            name of reporting persons     orbimed capital gp v llc  check the appropriate box if a member of a group see instructions a o b o        sec use only      source of funds see instructions   af  check box if disclosure of legal proceedings is required pursuant to items d or e     o  citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with  sole voting power     shared voting power     sole dispositive power     shared dispositive power     aggregate amount beneficially owned by each reporting person     check box if the aggregate amount in row  excludes certain shares see instructions     o  percent of class represented by amount in row      type of reporting person see instructions   oo  this percentage is calculated based upon  of the issuer’s ordinary shares outstanding including any such ordinary shares represented by adss defined below as set forth in the issuer’s form f filed with the sec defined below on october            schedule d   cusip no  a   page  of  pages            name of reporting persons     samuel d isaly  check the appropriate box if a member of a group see instructions a o b o        sec use only      source of funds see instructions   af  check box if disclosure of legal proceedings is required pursuant to items d or e     o  citizenship or place of organization   united states number of shares beneficially owned by each reporting person with  sole voting power     shared voting power     sole dispositive power     shared dispositive power     aggregate amount beneficially owned by each reporting person     check box if the aggregate amount in row  excludes certain shares see instructions     o  percent of class represented by amount in row      type of reporting person see instructions   in  this percentage is calculated based upon  of the issuer’s ordinary shares outstanding including any such ordinary shares represented by adss defined below as set forth in the issuer’s form f filed with the sec defined below on october              item  security and issuer   this amendment no  “amendment no ” to the schedule d filed with the securities and exchange commission the “sec” on may   the “statement” relates to the ordinary shares of adaptimmune therapeutics plc a public limited company organized under the laws of england and wales the “issuer”  certain ordinary shares are represented by american depositary shares “adss” with each ads representing six ordinary shares  the adss are listed on the nasdaq global select market under the ticker symbol “adap”  the issuer’s principal offices are located at  park drive milton park abingdon oxfordshire ox ry united kingdom   this amendment no  is being filed on a voluntary basis to report certain recent acquisitions of ordinary shares by the reporting persons defined in item  and to update the information in the statement relating to the beneficial ownership of ordinary shares including ordinary shares represented by adss by the reporting persons   item  identity and background   a           this amendment no  is being filed by orbimed advisors llc “advisors” a limited liability company organized under the laws of delaware orbimed capital gp v llc “gp v” a limited liability company organized under the laws of delaware and samuel d isaly “isaly” an individual collectively the “reporting persons”   b – c  advisors a registered investment adviser under the investment advisers act of  as amended is the sole managing member of gp v which is the sole general partner of orbimed private investments v lp “opi v” which holds ordinary shares including certain ordinary shares represented by adss as more particularly described in item  below  advisors has its principal offices at  lexington avenue th floor new york new york    gp v has its principal offices at  lexington avenue th floor new york new york    isaly a natural person is the managing member of advisors and owns a controlling interest in advisors   the directors and executive officers of advisors and gp v are set forth on schedules i and ii attached hereto  schedules i and ii set forth the following information with respect to each such person   i           name   ii          business address   iii         present principal occupation or employment and the name principal business and address of any corporation or other organization in which such employment is conducted and   iv         citizenship   d – e during the last five years neither the reporting persons nor any person named in schedule i or ii have been i convicted in a criminal proceeding excluding traffic violations or similar misdemeanors or ii a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment decree or final order enjoining future violations of or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws   f           isaly is a citizen of the united states   item  source and amount of funds or other consideration   the ordinary shares including ordinary shares represented by adss covered by this amendment no  have been acquired by the reporting persons with working capital of opi v and capital contributions made to opi v by its partners           item  purpose of transaction   the reporting persons caused opi v to acquire ordinary shares including ordinary shares represented by adss for the purpose of making an investment in the issuer and not with the intention of acquiring control of the issuer’s business on behalf of opi v   the reporting persons from time to time intend to review their investment in the issuer on the basis of various factors including the issuer’s business financial condition results of operations and prospects general economic and industry conditions the securities markets in general and those for the issuer’s ordinary shares in particular as well as other developments and other investment opportunities  based upon such review the reporting persons will take such actions in the future as the reporting persons may deem appropriate in light of the circumstances existing from time to time  if the reporting persons believe that further investment in the issuer is attractive whether because of the market price of the ordinary shares or otherwise they may acquire ordinary shares including in the form of adss or other securities of the issuer either in the open market or in privately negotiated transactions  similarly depending on market and other factors the reporting persons may determine to dispose of some or all of the ordinary shares currently owned by the reporting persons or otherwise acquired by the reporting persons either in the open market or in privately negotiated transactions   except as set forth in this amendment no  the reporting persons have not formulated any plans or proposals which relate to or would result in a the acquisition by any person of additional securities of the issuer or the disposition of securities of the issuer b an extraordinary corporate transaction such as a merger reorganization or liquidation involving the issuer or any of its subsidiaries c a sale or transfer of a material amount of the assets of the issuer or any of its subsidiaries d any change in the present board of directors or management of the issuer including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board e any material change in the issuer’s capitalization or dividend policy of the issuer f any other material change in the issuer’s business or corporate structure g any change in the issuer’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the issuer by any person h causing a class of the issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association i a class of equity securities of the issuer becoming eligible for termination of registration pursuant to section g of the act or j any action similar to any of those enumerated above   item  interest in securities of the issuer   ab    as of the date of this filing the reporting persons may be deemed for purposes of rule d of the act directly or indirectly including by reason of their mutual affiliation to be the beneficial owners of the ordinary shares described in item  above  based upon information contained in the issuer’s form f filed with the sec on october   such ordinary shares constitute approximately  of the issued and outstanding ordinary shares including any ordinary shares represented by adss  advisors pursuant to its authority as the sole managing member of gp v the sole general partner of opi v may be deemed to indirectly beneficially own the ordinary shares held by opi v  gp v pursuant to its authority as the general partner of opi v may be deemed to indirectly beneficially own the ordinary shares held by opi v  isaly pursuant to his authority as the managing member of advisors and owner of a controlling interest in advisors pursuant to its limited liability company agreement may also be deemed to indirectly beneficially own the ordinary shares attributable to advisors  as a result isaly advisors and gp v share the power to direct the vote and to direct the disposition of the ordinary shares described in item  above   c   date of transaction transaction number of shares price per share price range october   buy    to  october   buy    to             the price per share reported above is a weighted average price  upon request the reporting persons undertake to provide the issuer any security holder of the issuer or the sec full information regarding the ordinary shares represented by adss purchased at each separate price within the ranges set forth above except as disclosed in this item  the reporting persons have not effected any transactions in the issuer’s ordinary shares during the past sixty  days   d           not applicable   e           not applicable   item  contracts arrangements understandings or relationship with respect to securities of the issuer   in addition to the relationships between the reporting persons described in items   and  above gp v is the sole general partner of opi v pursuant to the terms of the limited partnership agreement of opi v  advisors is the sole managing member of gp v pursuant to the terms of the limited liability company agreement of gp v  pursuant to these agreements and relationships advisors and gp v have discretionary investment management authority with respect to the assets of opi v  such authority includes the power of gp v to vote and otherwise dispose of securities purchased by opi v  the number of outstanding ordinary shares held by opi v is  ordinary shares of which  are represented by  adss  advisors and gp v may each be considered to hold indirectly  ordinary shares  isaly pursuant to his authority as the managing member of and owner of a controlling interest in advisors also has shared discretionary power to direct the vote and the disposition of the securities of the issuer held by opi v   peter thompson “thompson” a private equity partner of advisors has been a member of the board of directors of the issuer since february  and a member of the board of directors of adaptimmune limited since september  and accordingly the reporting persons may have the ability to affect and influence control of the issuer  in connection with the issuer’s initial public offering thompson was awarded immediately exercisable options to purchase  ordinary shares the ordinary shares subject to these options are not included in the number of ordinary shares reported as held indirectly by gp v advisors and isaly  from time to time thompson may receive stock options or other awards of equitybased compensation pursuant to the issuer’s compensation arrangements for nonemployee directors  thompson is obligated to transfer any securities issued under any such stock options or other awards or the economic benefit thereof to the reporting persons which will in turn ensure that such securities or economic benefits are provided to opi v   registration rights   opi v and certain other stockholders of the issuer entered into an investors’ rights agreement with adaptimmune limited dated as of september    this agreement was terminated on february   and replaced by a substantively similar agreement by and among adaptimmune therapeutics limited and certain of its shareholders and adaptimmune limited dated february   the “investors’ rights agreement”  pursuant to the investors’ rights agreement and subject to the terms and conditions therein the parties agreed that   demand registration rights   at any time after the earlier of i september   or ii six months after the issuer’s initial public offering offering the holders of more than  of the registrable securities then outstanding have the right to demand that the issuer use its best efforts to file a registration statement provided that the anticipated aggregated offering price for such offering must exceed  million the issuer is only obligated to file up to two registration statements in connection with the exercise of demand registration rights  in addition the issuer will not be required to effect a demand registration during the period that is  days before the issuer’s good faith estimate of the date of filing of and ending on a date that is  days after the effective date of an issuerinitiated registration of its securities provided that the issuer is actively employing in good faith commercially reasonable efforts to cause its registration statement to become effective          f registration rights   at any time after the issuer becomes eligible to file a registration statement on form f any holder of registrable securities has the right to demand that the issuer use its commercially reasonable efforts to file a registration statement on form f covering at least  million of registrable securities the issuer is not obligated to file more than two such registration statements in any month period  in addition the issuer will not be required to effect a registration on form f during the period that is  days before the issuer’s good faith estimate of the date of filing of and ending on a date that is  days after the effective date of an issuerinitiated registration of its securities provided that the issuer is actively employing in good faith commercially reasonable efforts to cause its registration statement to become effective   piggyback registration rights   the investors’ rights agreement further provides that if the issuer proposes to register other than in a shelf registration any ordinary shares or adss representing such ordinary shares after the completion of the issuer’s initial public offering shareholders who have entered into the investors’ rights agreement are entitled to notice of such registration and to include their registrable securities in that registration the registration of such shareholders’ registrable securities pursuant to a company registration does not relieve the issuer of the obligation to effect a demand registration the managing underwriter has the right to limit the number of registrable securities included in a company registration if the managing underwriter believes it would interfere with the successful marketing of the ordinary shares or adss  these rights do not apply with respect to a registration related to employee benefit plans corporate reorganizations or certain other transactions described in rule  under the securities act a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the registrable securities or a registration in which the only ordinary shares being registered are ordinary shares issuable upon conversion of debt securities that are also being registered   expenses of registration   subject to limited exceptions the issuer will pay the registration expenses of the holders of the shares registered pursuant to the demand and piggyback registration rights described above   indemnification   the investors’ rights agreement contains customary crossindemnification provisions pursuant to which the issuer is obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the registration statement attributable to the issuer and the selling stockholders are obligated to indemnify the issuer for material misstatements or omissions attributable to them   termination of registration rights   opi v’s demand and piggyback registration rights described above generally will terminate upon the earliest of i the date five years following the issuer’s initial public offering ii a sale of the issuer as defined for purposes of the investors’ rights agreement or iii such time as rule  or another similar exemption under the securities act is available for the sale of all of the ordinary shares of the issuer including in the form of adss held by opi v without limitation during a threemonth period   the foregoing description of the investors’ rights agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the investors’ rights agreement a copy of which is included in this statement as exhibit  and incorporated herein by reference   other than as described in this schedule d to the best of the reporting persons’ knowledge there are no other contracts arrangements understandings or relationships legal or otherwise among the persons named in item  and between such persons and any person with respect to any securities of the issuer          item  materials to be filed as exhibits   exhibit description  joint filing agreement among orbimed advisors llc orbimed capital gp v llc and samuel d isaly  investors’ rights agreement by and among the issuer and each of the persons listed on schedule a thereto dated as of february   incorporated by reference to exhibit  to the issuer’s registration statement on form f sec  filed with the sec on april                                signature   after reasonable inquiry and to the best of each of the undersigned’s knowledge and belief each of the undersigned certifies that the information set forth in this amendment no  is true complete and correct   dated  november        orbimed advisors llc a delaware limited liability company               by  s samuel d isaly       name samuel d isaly       title managing member                         orbimed capital gp v llc a delaware limited liability company     by orbimed advisors llc a delaware limited liability company and its managing member                   by  s samuel d isaly       name samuel d isaly       title managing member                     samuel d isaly                     by  s samuel d isaly       name samuel d isaly                                schedule i   the name and present principal occupation of each of the executive officers and directors of orbimed advisors llc are set forth below  unless otherwise noted each of these persons are united states citizens and have as their business address  lexington avenue th floor new york ny    name position with reporting person principal occupation samuel d isaly managing member managing member orbimed advisors llc carl l gordon member member orbimed advisors llc sven h borho german and swedish citizen member member orbimed advisors llc jonathan t silverstein member member orbimed advisors llc w carter neild member member orbimed advisors llc geoffrey c hsu member member orbimed advisors llc evan d  sotiriou chief financial officer   chief financial officer orbimed advisors llc                     schedule ii   the business and operations of orbimed capital gp v llc are managed by the executive officers and directors of its managing member orbimed advisors llc set forth on schedule i attached hereto                             exhibit index   exhibit description  joint filing agreement among orbimed advisors llc orbimed capital gp v llc and samuel d isaly  investors’ rights agreement by and among the issuer and each of the persons listed on schedule a thereto dated as of february   incorporated by reference to exhibit  to the issuer’s registration statement on form f sec  filed with the sec on april                         elevate your investments try it for free orbimed advisors buys some more ascendis pharma asnd shares  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member hedge fundsnews orbimed advisors buys some more ascendis pharma asnd shares published on june   at  pm by insider monkey staff in hedge fundsnews page  of next gtgt samuel isaly‘s orbimed advisors has stepped up its interest in ascendis pharma as nasdaqasnd as reported in a recentlyamended filing with the securities and exchange commission orbimed’s stake in the company has been increased to  million shares or  of the common stock following the acquisition of  shares on june  at an average price of  apiece prior to that the fund had bought more than  shares on june  and  ascendis pharma as nasdaqasnd has a market cap of  million and does not pay a dividend the stock started the year in a down trend but it quickly recovered and was in green territory at the end of january the rally did not continue however and shares are currently down by  for the year having ended tuesday’s trading session at  per unit ascendis pharma swung to a loss for the first quarter of  as revenues tumbled by  yearoveryear to € million  million the company posted a net loss of € million  million or €  per share at the end of the first quarter roughly  of ascendis pharma as nasdaqasnd common stock was held by  of the funds followed by insider monkey down from  registered a quarter before peter kolchinsky‘s ra capital management is betting big on this stock having amassed  million shares worth  million at the end of march baker bros advisors’ manager julian baker and felix baker are also keeping an eye on ascendis pharma as their fund held  shares at the end of march unchanged over the course of the first quarter you can access the original sec filing by clicking here ownership summary table name sole voting power shared voting power sole dispositive power shared dispositive power aggregate amount owned power percent of class orbimed advisors       orbimed capital gp v       samuel d isaly       samuel isalyorbimed advisors page  of  – sec filing    united states securities and exchange commission washington dc  schedule d under the securities exchange act of  amendment no  ascendis pharma as name of issuer ordinary shares title of class of securities p cusip number orbimed advisors llc orbimed capital gp v llc samuel d isaly  lexington avenue th floor new york ny  telephone   name address and telephone number of person authorized to receive notices and communications june   date of event which requires filing of this statement if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of § de df or dg check the following box o note schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits see § db for other parties to whom copies are to be sent the remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page the information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section  of the securities exchange act of  “act” or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes follow ascendis pharma asfollow ascendis pharma as trade  now page  of next gtgt related insider monkey articleshere’s why jc penney bt group and three other stocks are on radarswhy are these five stocks trending todaybattered staffing company kornferry international kfy and two other companiesgold stocks are on the rise following brexit votethis week in tech tesla solarcity alibaba and morethis week in energy bp seadrill energy transfer and others ascendis pharma as nasdaqasnd orbimed advisors sec d filing yahoo finance insider monkey small cap strategy download a free copy of our newsletter and see the details inside hedge fund resource center how to beat the market by  percentage points why track hedge funds download a free edition why you should dump your hedge funds  things you didnt know about hedge funds related news imperva inc impv billionaire paul singer’s elliott reveals new stake united online inc untd cannell capital votes against merger with b riley financial federalmogul holdings corp fdml billionaire carl icahn raises offer to buy remaining stock jim roumell threatens covisint corp covs with a proxy fight unless the company is sold discovery group boosts stake in tubemogul inc tube voce capital dumps stake in fbr  co fbrc discovery group unwinds techtarget inc ttgt investment  countries that produce the most wind energy in the world  countries that export the most wine in the world  mostawaited products announced at e conference billionaire hedge funds warren buffett berkshire hathaway  david einhorn greenlight capital  george soros soros fund management  t boone pickens bp capital  jim simons renaissance technologies  leon cooperman omega advisors  carl icahn icahn capital lp  steve cohen point asset management  john paulson paulson  co  david tepper appaloosa management lp  about us contact us terms of use privacy policy next post home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved orbimed sells common shares of cynapsus therapeutics inc  marketwatch latest news dow    nasdaq    sp      pm et snap shares up   pm et updated student auto loans are biggest risks trump’s bank regulator nominees say  pm et nordstrom family members in talks with private equity partners including kkr to go private reuters  pm et updated stock market retreats from records as tech stocks swing to losses  pm et updated new rule forces big car makers into big changes in how they count revenues  pm et updated waters has testy exchange with mnuchin over trump financing  pm et amazons stock down  reversing earlier gain of as much as   pm et homeownership rate jumps from year low  pm et nordstrom family in talks with private equity partners including kkr about buyout reuters  pm et what are icos and why is the sec taking steps to protect investors from them  pm et updated dropping border adjustment plan limits taxreform push  pm et nordstrom shares up  in late trade  pm et dow transports tumble toward biggest selloff in over a year  pm et att set to unfurl largest corporate bond sale this year for time warner purchase  pm et updated treasury yields rebound on raft of solid economic data and att debt deal  pm et dow jones industrial average returns to positive territory  pm et updated whirlpool shares slide  after profit miss soft guidance  pm et updated nasdaq composite pivots sharply lower in afternoon trade  pm et updated the open road or the open skies millennials have made up their minds  pm et updated exxon earnings will stock trade higher on expected secondquarter beat log in until new york markets close market snapshot winners and losers home cnw group get email alerts orbimed sells common shares of cynapsus therapeutics inc by published sept    am et share new york sep   canada newswire via comtex  orbimed advisors llc reported today that on september   entities affiliated with it sold the sale  common shares common shares of cynapsus therapeutics inc cynapsus or the issuer such that orbimed as defined below now collectively beneficially owns controls and directs less than  of the outstanding common shares of cynapsus the common shares were sold by orbimed private investments v lp opi v orbimed capital gp v llc gp v is the sole general partner of opi v orbimed advisors llc advisors is the managing member of gp v mr samuel d isaly isaly is the managing member of advisors each of opi v gp v and advisors is organized under the laws of the state of delaware opi v gp v advisors and isaly are collectively hereinafter referred to as orbimed as a result of the sale orbimed now collectively beneficially owns controls and directs  common shares comprised of  common shares and warrants to purchase  common shares representing in aggregate  of the issued and outstanding common shares calculated based on the  common shares reported by the issuer as being outstanding as of august   orbimed also has ownership and control over additional warrants to purchase  common shares together with the warrants to purchase  common shares above the warrants the warrants contain an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise the holder together with the holders affiliates and any other persons acting as a group together with the holder or any of the holders affiliates would beneficially own in excess of  of the common shares outstanding immediately after giving effect to the issuance of the common shares issuable upon exercise of the warrants the blocker as a result of the blocker as of the date hereof  common shares are issuable upon exercise of the warrants as of september   the date immediately prior to the day of the sale orbimed collectively beneficially owned controlled and directed  common shares comprised of  common shares and the warrants of which no common shares were exercisable thereunder representing in aggregate  of the issued and outstanding common shares calculated based on the  common shares reported by the issuer as being outstanding as of august   the sale resulted in a decrease of orbimed collective beneficial ownership control and direction of  of the issued and outstanding common shares calculated based on the  common shares reported by the issuer as being outstanding as of august   the common shares were sold at a price of us per common share for total consideration less commission of us being c per common share and total consideration less commission of c using the bank of canadas september   noon exchange rate of us  c opi v holds the common shares for investment purposes and may depending on market and other conditions or as future circumstances may dictate from time to time on an individual or joint basis increase or decrease its beneficial ownership control or direction over common shares of the issuer through market transactions private agreements treasury issuances exercise of the warrants options other convertible securities or otherwise this press release is being issued pursuant to the requirements of national instrument   the early warning system and related takeover bid and insider reporting issues of the canadian securities administrators a copy of the report to be filed by orbimed in connection with the transactions described herein will be available on cynapsuss sedar profile at wwwsedarcom and can also be obtained by contacting douglas coon of orbimed at the telephone number listed below cynapsus is located at  richmond street west toronto ontario mj c the address of orbimed is  lexington avenue th floor new york ny  about orbimed orbimed is a leading investment firm dedicated exclusively to the healthcare sector orbimed invests globally across the spectrum of healthcare companies from venture capital startups to large multinational companies utilizing a range of private equity funds public equity funds royaltydebt funds and other investment vehicles orbimed maintains offices in new york city herzliya san francisco shanghai and mumbai source orbimed advisors llc to view this news release in html formatting please use the following url httpwwwnewswirecaenreleasesarchiveseptemberchtml source orbimed advisors llc orbimed douglas coon   copyright c  cnw group all rights reserved more from marketwatch more coverage the dark side of cruises stock market retreats from records as tech stocks swing to losses can snap fall even more as lockups expire most popular the dark side of cruises cocacola to replace coke zero in us stock market retreats from records as tech stocks swing to losses if you can buy only one stock or etf make it this one how to fix wall street and bankers pay marketwatch partner center we want to hear from you join the conversation comment sponsored headlines advanced search stocks columns authors topics no results found marketwatchcom topics bulletin investor alert new york markets close in market snapshot winners and losers topics istanbul brexit guns millennials immigration apple congatopicsmainhtml  subjects in the news us economy us politics earnings sales aerospace ice markets production iraq russia oil united kingdom europe european markets london markets health care income insurance people in the news jones edward trump donald woods tiger buffett warren putnam george clinton bill obama barack putin vladimir tillerson rex washington george ryan james walker david west david williams james gray john clooney george cruise tom jolie angelina companies in the news northrop grumman corp international data group new york mercantile exchange american international group health care insurance miners metal exchange target corp united national performance news corp jones oppenheimer international industries transport service capital one financial apple inc ebay inc organizations in the news american petroleum institute european union opec education department transportation department european central bank federal reserve bank of new york congress public service commission securities and exchange commission baseball nasdaq stock market consumers union world bank council on foreign relations security council senate boston college browse topics a b c d e f g h i j k l m n o p q r s t u v w x y z  log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest psnap shares up  pstudent auto loans are biggest risks trump’s bank regulator nominees say pnordstrom family members in talks with private equity partners including kkr to go private reuters pstock market retreats from records as tech stocks swing to losses pnew rule forces big car makers into big changes in how they count revenues pwaters has testy exchange with mnuchin over trump financing pamazons stock down  reversing earlier gain of as much as  phomeownership rate jumps from year low pnordstrom family in talks with private equity partners including kkr about buyout reuters pwhat are icos and why is the sec taking steps to protect investors from them pdropping border adjustment plan limits taxreform push pnordstrom shares up  in late trade pdow transports tumble toward biggest selloff in over a year patt set to unfurl largest corporate bond sale this year for time warner purchase ptreasury yields rebound on raft of solid economic data and att debt deal pdow jones industrial average returns to positive territory pwhirlpool shares slide  after profit miss soft guidance pbreakingnasdaq composite pivots sharply lower in afternoon trade pexxon earnings will stock trade higher on expected secondquarter beat pthe open road or the open skies millennials have made up their minds loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  insider trading  orbimed global healthcare gp llc  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  orbimed global healthcare gp llc select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector    indirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view conversion  pm nana intellia therapeutics inc ntla orbimed advisors llcorbimed capital gp v llcorbimed global healthcare gp llcisaly samuel ddirector   indirect view   secformcom all rights reserved archives        thu  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  orbimed acquires common shares of cynapsus therapeutics inc fr × member sign in online member centre cision communications cloud cision pr edition cisionpoint mediasource monitoringevaluation visible intelligence fastfinder my cnw cnw access register for my cnw close × search search go  advanced search close see more news releases in health care  hospitals acquisitions mergers and takeovers orbimed acquires common shares of cynapsus therapeutics inc new york july   cnw  orbimed advisors llc reported today that on july   entities affiliated with it acquired the acquisition  common shares common shares of cynapsus therapeutics inc cynapsus or the issuer such that orbimed as defined below now collectively beneficially owns controls and directs more than  of the outstanding common shares of cynapsus the common shares were acquired by orbimed private investments v lp opi v orbimed capital gp v llc gp v is the sole general partner of opi v orbimed advisors llc advisors is the managing member of gp v mr samuel d isaly isaly is the managing member of advisors each of opi v gp v and advisors is organized under the laws of the state of delaware opi v gp v advisors and isaly are collectively hereinafter referred to as orbimed as a result of the acquisition orbimed now collectively beneficially owns controls and directs  common shares representing in aggregate  of the issued and outstanding common shares calculated based on the  common shares reported by the issuer as being outstanding as of may   orbimed also has ownership and control over warrants to purchase  common shares the warrants the warrants contain an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise the holder together with the holders affiliates and any other persons acting as a group together with the holder or any of the holders affiliates would beneficially own in excess of  of the common shares outstanding immediately after giving effect to the issuance of the common shares issuable upon exercise of the warrants the blocker as a result of the blocker as of the date hereof no common shares are issuable upon exercise of the warrants as of july   the date immediately prior to the day of the acquisition orbimed collectively beneficially owned controlled and directed  common shares comprised of  common shares and the warrants of which  common shares were exercisable thereunder representing in aggregate  of the issued and outstanding common shares calculated based on the  common shares reported by the issuer as being outstanding as of may   and the assumption that the  common shares exercisable under the warrants were issued and outstanding the acquisition resulted in an increase of orbimed collective beneficial ownership control and direction of  of the issued and outstanding common shares calculated based on the  common shares reported by the issuer as being outstanding as of may   the common shares were acquired at a price of us per common share for total consideration paid of us being c per common share and total consideration of c using the bank of canadas july   noon exchange rate of us  c opi v acquired the common shares for investment purposes and may depending on market and other conditions or as future circumstances may dictate from time to time on an individual or joint basis increase or decrease its beneficial ownership control or direction over common shares of the issuer through market transactions private agreements treasury issuances exercise of the warrants options other convertible securities or otherwise this press release is being issued pursuant to the requirements of national instrument   the early warning system and related takeover bid and insider reporting issues of the canadian securities administrators a copy of the report to be filed by orbimed in connection with the transactions described herein will be available on cynapsuss sedar profile at wwwsedarcom and can also be obtained by contacting douglas coon of orbimed at the telephone number listed below cynapsus is located at  richmond street west toronto ontario mj c the address of orbimed is  lexington avenue th floor new york ny  about orbimed orbimed is a leading investment firm dedicated exclusively to the healthcare sector orbimed invests globally across the spectrum of healthcare companies from venture capital startups to large multinational companies utilizing a range of private equity funds public equity funds royaltydebt funds and other investment vehicles orbimed maintains offices in new york city herzliya san francisco shanghai and mumbai source orbimed advisors llc for further information orbimed douglas coon   release contains wide tables view fullscreen organization profile orbimed advisors llc more on this organization custom packages browse our custom packages or build your own to meet your unique communications needs start today cnw membership fill out a cnw membership form or contact us at    learn about cnw services request more information about cnw products and services or call us at    orbimed english  portfolio immunotherapy gene therapy gene editing the future of health sciences is closer than you think many technologies with the potential to cure disease are advancing rapidly how long can healthy humans live  years  years our portfolio companies are working hard to find out industry sector all biopharmaceutical diagnosticstools healthcare services medical device healthcare it region all asia middle east north america europe sort by alphabetical newest oldest acutus developing a novel electroanatomical mapping catheter more adaptimmune focused on the use of t cell therapy to treat cancer more adicet bio adicet bio inc is developing a novel universal immunecell more adimab fully integrated yeastbased antibody discovery maturation and more aeglea biotherapeutics developing novel treatments using engineered human amino more aerpio developing treatments for disorders of the vasculature with more affimed discovering and developing next generation antibody therapies more aige hospital a leading eye hospital chain in the central region of china more aims multispecialty tertiary care hospital in north india more ait applied immune technologies ait is a drug development more ak medical developing a novel electroanatomical mapping catheter for more alector developing antibody therapeutics to treat more alpine immune sciences alpine immune sciences is focused on developing novel more amoy diagnostics the leader in cancer molecular diagnostics in china more armo biosciences discovering and developing novel immunooncology drugs more arsanis biosciences developing antibody therapeutics for infectious diseases more arvinas arvinas is a pharmaceutical company focused on developing more ascendis pharma ascendis pharma develops differentifaated prodrug versions more atox bio atox bio is a late stage biotechnology company that develops more audentes therapeutics developing gene therapy products for rare diseases more augmedix augmedix commercializes a service that frees doctors from more avedro inc avedro is a privately held medical device and more avitide developing custom affinity purification solutions for more balance therapeutics balance therapeutics is an rd company focused on more bharat serums and vaccines developing and manufacturing a wide range of products such more biolinerx building a portfolio of products for various indications more bonovo orthopedics providing the latest orthopedic products to the more cbt pharmaceuticals a spinoff from crown biosciences dedicated to oncology more cerapedics developing and commercializing products for the orthopedic more chemclin a leader to provide affordable diagnostics products more chemomab chemomab is developing therapeutic antibodies as more cleave biosciences discovering and developing therapeutics targeting more clementia developing treatments for diseases of heterotopic more compass therapeutics compass therapeutics is seeking to cure various cancer more corvus pharmaceuticals developing novel immunotherapies for the treatment of cancer more credit pharma credit pharma is a central nervous system focused leading more crown bioscience a preclinical cro with leadership in translational oncology more dih a leading provider of robotics and intelligent systems more dimension therapeutics developing aav therapeutics for rare diseases more domain surgical develops and commercializes a thermal surgical energy more echosens french hightechnology company specializing in more eddingpharm commercializing a broad range of pharmaceutical products in more emendo biotherapeutics emendo develops biotherapeutics based on its novel gene editing more eurolife healthcare one of india’s leading manufacturers of intravenous iv fluids more futurx pharma incubator established with jj and takeda more gc aesthetics develops and manufactures breast and aesthetic implants for more gcrise pharmaceutical a leading chinese pharmaceutical company focused on women more genewiz a leading global genomics service company more glaukos transforming glaucoma therapy more good start genetics developing improved methods of prepregnancy testing more graybug vision graybug vision is developing products to reduce the frequency of more guardant health guardant health is a private diagnostics company focusing on more hls therapeutics hls therapeutics is a specialty pharmaceutical more igenica discovering and developing breakthrough more inspire medical systems developed implanted neurostimulation device for more intellia therapeutics intellia is a leading gene editing company focused on more intercept developing therapeutics for liver  metabolic diseases more invitae offering  genetic diagnostics for hereditary disorders more kala pharmaceuticals kala pharmaceuticals is a clinical stage pharmaceutical more keystone heart developing procedural tools and accessories for use during more laxmi dental leading dental laboratory in india manufacturing dental more logicbio logicbio develops gene therapy vectors for previously more loxo oncology developing targeted cancer therapies for more marinus pharmaceuticals marinus pharmaceuticals is a clinical stage more mdclone mdclone was founded to address one of the most critical more medigus developing innovative endoscopic procedures and devices more mid labs an innovative ophthalmic medical device company with more nabriva developing pleuromutilins a new class of antibiotics more natera provides preconception and prenatal genetic testing more nerre therapeutics nerre therapeutics is developing a portfolio of neurokinin more netmedscom netmedscom is a leading online pharmacy marketplace in india more nextcure nextcure is a biopharmaceutical company focused on more novellusdx a personalized medicine diagnostics company assessing the more nucleix nucleix develops manufactures and markets more nutrinia nutrinia treats rare diseases of the gi tract by developing more obseva sa obseva is a swissbased pharmaceutical company developing small more omniguide surgical develops and markets an advanced surgical energy delivery more oric pharmaceuticals oric pharmaceuticals is focused on discovering and more ornim medical developing devices monitoring hemoglobin blood more otic pharma oticpharma is seeking to develop ear nose and throat products more otonomy developing novel drug therapies for disorders of the inner more oxonc development conducting clinical studies of xalkori in ros advanced more pharmabcine developing fully human therapeutic antibodies for the more pharming group nv netherlandsbased public biotechnology company more pieris ag discovering and developing anticalins® a novel class more pionyr immunotherapeutics pionyr is developing cancer immunotherapies that target the more pmv pharma developing p modulators for the treatment of cancer more practice fusion a leading provider of electronic healthcare record services more principia biopharma developing novel therapeutics using reversible more promentis pharmaceuticals promentis is developing compounds for the treatment of cns more proteus digital health proteus is a private digital medicine platform company more rapid pathogen screening marketer of rapid pointofcare diagnostic tests more rdd pharma developing drugdevice combinations for the treatment more recro pharma clinical stage specialty pharmaceutical company more redhill biopharma developing late clinicalstage formulations and combinations more response biomedical corp manufactures and markets rapid onsite diagnostic tests more reviral reviral is an emerging ukbased biopharma aiming to more rhythm pharmaceuticals rhythm is a biopharmaceutical company developing more roka bioscience commercializing novel nucleic acid testing methods more rpharm rpharm us is a specialty pharmaceutical company focused on more scpharmaceuticals scpharmaceuticals is developing a portfolio of pharmaceutical more selecta biosciences developing firstinclass integrated synthetic more senico healthcare leading provider of kidney and specialty care services in the more sibone commercializing the ifuse implant system for minimally more sientra inc developing products for the plastic surgery and more sierra oncology sierra oncology is a clinical stage drug development company more sikka software enhancing practice economics and improving quality of care more singulex developing and commercializing the next generation of more smartzyme smartzyme innovation is a life science company using a more sonendo developing innovative devices for root canal treatment more steadymed steadymed is a specialty pharmaceutical company focused on the more strides shasun service provider to the global pharmaceutical industry more suraksha diagnostic leading diagnostic chain in east india more surya a prominent neonatal and pediatric care hospital chain more symbiomix therapeutics a new focus on womens health more syndax pharmaceuticals syndax is a latestage biopharmaceutical company more synlogic synlogic engineers synthetic biotics a new class of medicines more tela bio developing novel biologic mesh implant products more therachon therachon is a biotech company specialized in research and more tigertext provides secure messaging in healthcare applications more tp therapeutics tp therapeutics is a clinicalstage biopharmaceutical company more treato the voice of the patient  big data analytics of patient more tricida preclinical stage biopharmaceutical company focused on more turnstone biologics turnstone is developing a firstinclass engineered oncolytic more tyto tytocare provides the missing link in telehealth  a more unilife develops and supplies injectable drug delivery systems more upper biotech a leading poct diagnostics company in china more verona pharma verona pharma is a ukbased clinical stage biopharmaceutical more viewray developing next generation radiotherapy technologies more waterstone pharmaceuticals chinabased specialty pharmaceutical company more whale imaging developing and commercializing medical imaging solutions more xenon pharmaceuticals xenon is a clinicalstage biopharmaceutical company discovering more xtant medical xtant medical is a comprehensive supplier of orthopedic more zai labratory a leading biotech company based in china more load more our team has helped nurture and commercialize some of todays most successful healthcare companies meet our team